Research programme: cardiac cell reprogramming - LoneStar Heart

Drug Profile

Research programme: cardiac cell reprogramming - LoneStar Heart

Latest Information Update: 02 Aug 2016

Price : $50

At a glance

  • Originator University of Texas Southwestern Medical Center
  • Developer LoneStar Heart
  • Class Cell therapies; Ischaemic heart disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Ischaemic heart disorders

Most Recent Events

  • 02 Aug 2016 Preclinical trials in Ischaemic heart disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top